Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933463 | 1.00 | TAAR1 (0.37) | TAAR1GABRA1GABRB2IDO1MEP1B | |
| SCHEMBL960397 | 0.85 | GABRA1 (0.36) | TAAR1GABRA1GABRB2IDO1MEP1B | |
| SCHEMBL27885744 | 0.82 | TAAR1 (0.39) | TAAR1GABRA1GABRB2IDO1MEP1B | |
| SCHEMBL1363756 | 0.81 | TAAR1 (0.46) | TAAR1GABRA1GABRB2IDO1KDM1A | |
| SCHEMBL28668675 | 0.81 | TAAR1 (0.37) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL30758607 | 0.80 | KDM1A (0.38) | KDM1AKCNH2KDM1B | |
| SCHEMBL6121258 | 0.80 | KDM1A (0.38) | KDM1AKCNH2KDM1B | |
| SCHEMBL15351717 | 0.79 | GABRA1 (0.39) | TAAR1GABRA1GABRB2IDO1MEP1B | |
| SCHEMBL332641 | 0.79 | TAAR1 (0.35) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL18611530 | 0.79 | GABRA1 (0.56) | TAAR1GABRA1GABRB2IDO1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330229-B1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-12-17 | — | — | EP | claimed |
| US-20240228437-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-11 | — | — | US | claimed |
| EP-4330229-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2024-03-06 | — | — | EP | claimed |
| CN-117529470-A | Method for producing pyrrolidine compounds | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | claimed |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260042733-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-12-23 | — | — | US | disclosed |
| EP-4323354-B1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| EP-4330229-B1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-12479798-B2 | Method for producing pyrrolidine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20080269302-A1 | Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2008-10-30 | — | — | US | disclosed |
| CN-101133029-A | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2008-02-27 | — | — | CN | disclosed |
| EP-1814537-A2 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006055434-A2 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-5489592-A | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETES-RELATED DISORDERS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1996-02-06 | — | — | US | disclosed |
| EP-0607344-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007109-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-04-15 | — | — | WO | disclosed |
| US-4331821-A | ULTRAVIOLET RADIATION OF A VAPORIZED ALKYLBENZEN AND HALOGEN GAS MIXTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | HCRTR2, HCRTR1, CRHR2 | TAAR1 544/4885GABRA1 123/4885GABRB2 109/4885 |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | TAAR1 3696/4885GABRA1 3496/4885GABRB2 3219/4885 |
| US-20260042733-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | PAH, TYR, PIM2 | TAAR1 2099/4885GABRA1 1015/4885GABRB2 1398/4885 |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MTNR1B | TAAR1 164/4885GABRA1 108/4885GABRB2 179/4885 |
| US-20080269302-A1 | Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | TAAR1 1450/4885GABRA1 3332/4885GABRB2 2649/4885 |
| US-20240228437-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | PAH, SPR, IL4I1 | TAAR1 1417/4885GABRA1 1564/4885GABRB2 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.